Table 1.
Clinical characteristics of the study cohort. Data are expressed as absolute numbers or mean with either range or percentage. Disease severity was classified according to the WHO Progression Scale. Immunising events were defined as the diagnosis of SARS‐CoV‐2 infection by PCR from a nasopharyngeal swab or administration of a vaccine
| SARS‐CoV‐2 infection | SARS‐CoV‐2 vaccination | SARS‐CoV‐2 infection and vaccination | |
|---|---|---|---|
| (COVID‐19) | (V2/V3) | (IV/VI) | |
| n = 8 | n = 16 | n = 11 | |
| Age in years (range) | 54.9 (21–82) | 35.3 (21–56) | 54 (23–95) |
| Sex at birth | |||
| Male (%) | 7 (87.5%) | 6 (37.5%) | 7 (63.64%) |
| Female (%) | 1 (12.5%) | 10 (62.5%) | 4 (36.36%) |
| Disease severity | |||
| Uninfected – WHO 0 (%) | – | 16 (100%) | – |
| Ambulatory mild disease – WHO 1–3 (%) | 1 (12.5%) | – | 6 (54.55%) |
| Hospitalised: moderate disease – WHO 4–5 (%) | 2 (25%) | – | 4 (36.36%) |
| Hospitalised: severe disease – WHO 6–9 (%) | 4 (50%) | – | – |
| Unknown | 1 (12.5%) | – | 1 (9.09%) |
| Vaccination regime | |||
| 1 dose mRNA (%) | – | – | 2 (18.18%) |
| 1 dose vector (%) | – | – | 2 (18.18%) |
| 2 doses mRNA/mRNA (%) | – | 4 (25%) | 3 (27.27%) |
| 2 doses vector/mRNA (%) | – | 5 (31.25%) | 1 (9.1%) |
| 3 doses mRNA/mRNA/mRNA (%) | – | 4 (25%) | – |
| 3 doses vector/mRNA/mRNA (%) | – | 2 (12.5%) | – |
| 4 doses vector/mRNA/mRNA/mRNA (%) | – | 1 (6.25%) | – |
| Unknown | – | – | 3 (27.27%) |
| Time since last immunising event in days (range) | 88.0 (8–448) | 60.7 (3–196) | 80.1 (1–179) |